Celentyx is a human immune system focused R&D and service company.
Celentyx’s unique Immuno-Profiling™ platform allows rapid analysis of drug action on human immune cells. Drawing on the World-leading expertise of Celentyx personnel, which along with our close association with the MRC Centre for Immune Regulation, enables the human immune system to be investigated at the highest levels of resolution.
Celentyx's Immuno-Profiling™ services enable partners to elucidate the mechanism of action of an immunomodulatory drug, facilitate lead candidate prioritisation or identify potentially negative impact of a drug on the human immune system prior to first administration to man.
Celentyx's Novel Clinical Indication Profiling™, which applies the powerful Immuno-Profiling™ platform to the development of reprofiled drug candidates for diseases of the human immune system (e.g. inflammation, autoimmune disease, allergy, graft rejection, lymphoma, leukaemia), has created an increasing portfolio of valuable drug targets.
Professor John Gordon, Co-founder and CSO, introduces Celentyx Ltd's capabilities to investigate the human immune system.
For information please contact Dr Catherine Brady (email@example.com)